Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks - Wikidata - wikimedia - TriplyDB

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks

http://www.wikidata.org/entity/Q34960686

about

Prostate cancer: ESMO Consensus Conference Guidelines 2012 Cognitive impairment among prostate cancer patients: An overview of reviews.High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells.Risk stratification in the hormonal treatment of patients with prostate cancer The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis.New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks.Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy.National survey addressing the information needs of primary care physicians: Side effect management of patients on androgen deprivation therapy.Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.Triptorelin embonate: a 6-month formulation for prostate cancer.Androgen regulation of prostate cancer: where are we now?Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.Landmarks in hormonal therapy for prostate cancer.The status of surgery in the management of high-risk prostate cancer.Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners.Changes in Body Image in Patients with Prostate Cancer over 2 Years of Treatment with a Gonadotropin-Releasing Hormone Analogue (Triptorelin): Results from a Belgian Non-Interventional Study.Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix.Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy.Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.Androgen ablation for low-risk prostate cancer is common among male hip fracture patients.Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.Outcomes in men with large prostates (≥ 60 cm(3)) treated with definitive proton therapy for prostate cancer.Clinical pathway improves implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects in men with prostate cancer.Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries.A cohort study of digoxin exposure and mortality in men with prostate cancer.Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study.The health and well-being of prostate cancer patients and male-to-female transsexuals on androgen deprivation therapy: a qualitative study with comments on expectations and estrogen.Neoadjuvant hormonal therapy does not impact the treatment success of high-intensity focused ultrasound for the treatment of localized prostate cancer.The language of prostate cancer treatments and implications for informed decision making by patients.Performance of prostate cancer recurrence nomograms by obesity status: a retrospective analysis of a radical prostatectomy cohort

P2860

Q27022847-7090C456-C1FD-4BBC-91B2-861AA5DF8AF7 Q30236039-0BB04627-E2FC-4DB8-9160-DE35123F6AB8 Q33582598-7988DACA-846C-4B40-8A5F-645FDFCFBD20 Q33647720-31633159-E10F-403C-8899-5ADE98E99A18 Q35076189-B746B63D-3AE1-4AA0-B067-F2524AC5B950 Q35882782-67EBE06D-134C-491B-93DE-6A541ECAFC5E Q36070721-3736D4A3-8872-4A31-9697-007582086902 Q36734036-F5075BE3-80CA-4DD5-8F94-2248FFDCE37D Q36900784-DC063E8A-5EAE-4C76-B7AF-9148BBCCFD63 Q37085223-030715AE-CFAF-40B9-B87A-CF387411A144 Q37153672-A89D98C0-5E51-41D3-917A-76C5CA23D31A Q37726879-DBC3605D-8CE3-4CE0-9A3F-A0122D468AAB Q37790704-4F011D3A-4659-4CF4-89C6-C1FABEE133A7 Q37802378-410C23E8-3624-44D6-8AC0-CC26AEF24513 Q37836264-26FDBC38-6A8E-4669-89C8-85CD39669D79 Q38016531-6447634B-7F22-4101-A90D-5C408BA2F888 Q38050466-743AC7FA-D53F-4FF7-B98B-A0F3E3F39A58 Q38211115-3EE30D1A-13F7-44D5-95C2-7A782C8F1D79 Q38587219-D6B59184-6051-4E2E-8CEC-B0E8C90714DA Q39615780-EA5A1863-E8C0-4DFE-A692-98FA5088568B Q40770382-E87B0F9E-265F-4CDF-9029-B47EC1114B39 Q41930886-5A6636C4-C4AF-44A4-9692-F45C03B2FCCE Q42046396-3AEC45A9-7757-45CA-9761-AB6454E49B88 Q42223195-AE09BA53-6AC5-421D-A899-08A267FF6FDE Q43493188-42FF7C60-CA57-40F0-955A-DD4481ABE96F Q43720651-6CFFADB9-0C30-40F2-AD1F-12DE57EA6D5B Q45542064-D6F0A555-2CE9-4015-80D9-5328FA2A4DE4 Q47384120-DE24FD61-BFF4-486D-91C7-D5CC9A3044B0 Q47701404-34538B4C-7AB8-4E49-ACAE-CC3B9A20F54E Q47797325-E7E10BF9-7EDE-4B93-B787-B74D146FA20B Q48084722-78F7C486-B0C8-44A9-B573-29BBCD8EE74C Q48322804-756990CA-A9DE-4FCD-A4EA-AFB32F3EA94B Q50246619-34C16D28-6010-4956-B9DC-43A5EFAE3EBF Q51340619-EF84833B-6F39-4DED-80D5-E3FEB838387D Q58613630-0993EBD5-FC9E-412A-80CB-A695949EEE96

P2860

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks

http://www.wikidata.org/entity/Q34960686

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Androgen deprivation therapy f ...... nsider both benefits and risks

@ast

Androgen deprivation therapy f ...... nsider both benefits and risks

@en

Androgen deprivation therapy f ...... nsider both benefits and risks

@nl

type

label

Androgen deprivation therapy f ...... nsider both benefits and risks

@ast

Androgen deprivation therapy f ...... nsider both benefits and risks

@en

Androgen deprivation therapy f ...... nsider both benefits and risks

@nl

prefLabel

Androgen deprivation therapy f ...... nsider both benefits and risks

@ast

Androgen deprivation therapy f ...... nsider both benefits and risks

@en

Androgen deprivation therapy f ...... nsider both benefits and risks

@nl

P1433

Q34960686-52D645DD-492E-4D03-9334-15BEB60ED4C7

P1476

Q34960686-240EA5A9-7816-4C52-B6E8-3272FA08257D

P2093

Q34960686-40DA26DB-F43B-4247-9518-F8D1EB0B46C8

Q34960686-4519761C-FF84-4D76-8143-EAA68831E326

Q34960686-48E7C183-4173-4EE5-81AA-540D6478FE16

Q34960686-6F85AC6A-5080-4C01-AD86-8623CC046BA6

Q34960686-95B35400-BFAD-491E-BCEB-C413895C2656

Q34960686-A84AE504-729C-44D9-8632-F8EEA3A071E6

Q34960686-B6819A31-CFED-4896-8471-5CF781570BA0

P2860

Q34960686-046447D4-0B29-49ED-8830-110FE4770002

Q34960686-0621514D-9270-4E6F-813B-94788CF07555

Q34960686-07639EB1-7206-42E4-98C8-20D07EA050F0

Q34960686-09EE00B9-498B-4D3A-BAEB-383EFB103412

Q34960686-0BAB819A-7AE4-4A6F-8372-699B8ACDDB1D

Q34960686-116B540A-2EAD-426F-8F6D-B62F21126019

Q34960686-14616693-73E5-4CBE-AC09-8B5DE0CA2728

Q34960686-14F2E413-38BB-4398-8A98-01B4ACC9C0B2

Q34960686-18402800-5FE1-4E22-974E-4FF3CE7A388C

Q34960686-1A670E8A-31DE-4B50-A8E8-5609A8CAA367

P304

Q34960686-23D5F2E7-4C90-4462-8F9C-2E294792CF32

P31

Q34960686-43F8259F-AE7A-463F-9993-F5659906AADD

P356

Q34960686-E5925B35-B6C9-4DBD-BF4C-B6E581967526

P407

Q34960686-E727C35F-FE7C-46BC-9DE2-7A9E1D7ECC62

P433

Q34960686-56EF11B8-215D-46A6-A214-B3E650F0DC25

P478

Q34960686-3053D2D1-98E8-4459-8C9A-99024A3D11B6

P50

Q34960686-2FCA70E3-CDC5-44D0-905B-0ECB761575BF

P577

Q34960686-9DEE39D3-4DB2-4865-9BDB-E2DCB2F73DB6

P5875

Q34960686-BE1B7C14-8D26-4518-AC91-EBFF6C5EE228

P698

Q34960686-8A80C314-8CCC-41B6-9731-AB243BF97817

P932

Q34960686-E07B3FDF-B7AA-4BBF-8892-DB4C154E19DD

P356

J.EURURO.2008.10.008

P1433

European Urology

P1476

Androgen deprivation therapy f ...... nsider both benefits and risks

@en

P2093

Claude Schulman

http://www.w3.org/2001/XMLSchema#string

Cora N Sternberg

http://www.w3.org/2001/XMLSchema#string

Hendrik Isbarn

http://www.w3.org/2001/XMLSchema#string

Laurent Boccon-Gibod

http://www.w3.org/2001/XMLSchema#string

Matthew R Smith

http://www.w3.org/2001/XMLSchema#string

Peter R Carroll

http://www.w3.org/2001/XMLSchema#string

Urs E Studer

http://www.w3.org/2001/XMLSchema#string

P2860

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

Frailty in older adults: evidence for a phenotype

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

Natural history of progression after PSA elevation following radical prostatectomy.

Testosterone, body composition and aging.

Osteoporosis in men.

Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

P304

62-75

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2008.10.008

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Montorsi

P577

2008-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23409403

http://www.w3.org/2001/XMLSchema#string

P698

18945543

http://www.w3.org/2001/XMLSchema#string

P932

3090670

http://www.w3.org/2001/XMLSchema#string